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Conclusion: hTERT transcription up-regulated by E6 through the 
increase of c-Myc and HIF-1α strongly supports our previous studies 
indicating that HPV 16/18 infection could be involved in lung tumori-
genesis. hTERT mRNA may be an independent prognostic factor in 
lung cancer, especially in HPV 16/18 E6 positive lung cancer.
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Background: In 1999, WHO deﬁned atypical adenomatous hyper-
plasia (AAH) as preinvasive lesion of adenocarcinoma. Recently, we 
developed two immortalized cell lines of AAH (PL16T) and its coun-
terpart, bronchial epithelium (PL16B) by transfection of SV40 large T 
antigen (Shimada A et al, Cancer Sci. 96:668-675,2005). Using the two 
cell lines, differentially expressed genes in AAH cells were screened by 
cDNA microarray analysis. 
Methods: Total RNA was extracted from PL16T and PL16B, re-
spectively, and examined using cDNA microarray (CodeLink Human 
Whole Genome Bioarray, GE Health Care, USA) To conﬁrm the 
differences in expression levels of genes selected by cDNA microar-
ray analysis, quantitative real-time PCR (qRT-PCR) assay were carried 
out using PL16T and PL16B. Then, the expression differences of the 
selected genes were further examined using total RNA extracted from 
24 small sized adenocarcinomas (less than 2 cm in diameter) by qRT-
PCR assay. The 24 small sized adenocarcinomas contained 7 in situ 
adenocarcinomas (Bronchioloalveolar carcinoma (BAC); type A and 
B), 14 early invasive adenocarcinomas (mixed adenocarcinoma with 
BAC component; type C) and 3 poorly differentiated adenocarcinomas. 
Results: Totally, the expression level of 30298 genes was compared 
between PL16T and PL16B and fourteen genes were expressed 7 times 
or more in PL16T than PL16B. Among the 14 genes, we succeeded to 
compare the expression differences of 7 genes between the two cell 
lines by qRT-PCR and selected two genes that were expressed 10 times 
more in PL16T thanPL16B. The two genes are Sushi domain contain-
ing 2 (SUSD2) and Neuromedin U (NUM). About the two genes, we 
examined their expressions using 24 small sized adenocarcinomas by 
qRT-PCR. SUSD2 was expressed signiﬁcantly more in situ adenocar-
cinomas than normal lung tissue (p=0.022), but decreased in early in-
vasive adenocarcinoma (p<0.01). On the other hand, NMU expression 
was gradually increased according to the malignant progression from 
in situ carcinoma to early invasive adenocarcinoma, It was expressed 
signiﬁcantly more in early invasive adenocarcinoma than normal lung 
tissue (p=0.043). 
Conclusions: Using immortalized AAH and normal cell lines and 
cDNA microarray, we detected two speciﬁc genes (SUSD2 and NMU) 
that express differentially between early adenocarcinoma and normal 
tissue. The expression pattern of SUSD2 and NMU in early stage 
adenocarcinoma was different. SUSD2 expression is thought to be 
related to carcinogenesis, but NMU expression may be associated with 
malignant progression.
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Background: Pulmonary neuroendocrine tumors (NET) are a distinct 
subset of tumors composing approximately 20% of all lung cancers. 
Although they are classiﬁed into different categories in 2004 World 
Health Organization (WHO) system, their clinical characteristics 
are variable and range from indolent to aggressive. This study was 
conducted to investigate the clinical value of L1 cell adhesion molecule 
(CAM) in pulmonary NE tumors. 
Methods: We retrospectively analyzed L1-CAM expression in 71 cases 
of pulmonary NE tumors with diverse histological types by immuno-
histochemistry with monoclonal antibody A10-A3 (manufactured by 
HJ Hong). We evaluated the correlation of L1-CAM expression with 
WHO classiﬁcation and various clinicopathological factors, including 
overall survival. 
Results: L1 immunoreactivity was detected in 49 (69%) of all 71 
pulmonary NE tumors. L1-CAM immunoactivity was detected in 2 
(13.3%) of 15 typical carcinoids, 5 (71.4%) of 7 atypical carcinoids, 27 
(81.8 %) of 33 large-cell neuroendocrine carcinomas, and 15 (93.8%) 
of 16 small cell lung carcinomas, respectively. The percentage of 
L1-CAM expression increased with the aggressiveness and progres-
sion of tumors. With median 2.6 years (range: 0.03-10.9) of follow-up 
duration, the 5-year overall survival rates were 81.9% (n=18) for L1-
CAM negative group, 69.2% (n=9) for 1+ group, 47.1% (n=8) for 2+ 
group and 31.6% (n=6) for 3+ group, respectively (P<0.001, log-rank 
test). In multivariate analyses, age >55 years (P=0.007, HR 3.754, 
95% CI= 1.261-11.180) and high L1-CAM expression greater than 
20% (P=0.008, HR=2.893, 95% CI=1.255-6.669) were statistically 
signiﬁcant independent poor prognostic factors. The high L1-CAM 
expression group (≥20% of the carcinoma cells stained) demonstrated 
an approximately 3-fold increased risk of death over patients with low 
L1-CAM expression group (<20% of tumor cells stained). Patients in 
locally advanced disease stage (P=0.002, HR=3.835, 95% CI=1.612-
9.123) and advanced stage (P<0.001, HR=13.001, 95% CI=4.355-
38.808) also had signiﬁcantly poor prognosis over patients with local-
ized stage of pulmonary NET.
Conclusion: These results suggest that L1-CAM immunoreactivity 
may be useful as diagnostic and prognostic marker in pulmonary neuro-
endocrine tumors.
